Tin tức & Cập nhật

Stroke, a common cause of donor brain death, exhibits a substantially different effect on recipient and allograft survival depending on the age of the donor, suggests a recent study. Among younger donors, stroke contributes to increased recipient mortality and allograft failure than other causes of brain death.

Androgen deprivation therapy (ADT) does not seem to aggravate the likelihood of major adverse cardiovascular events (MACEs) in prostate cancer patients after curative radiotherapy (RT), according to a recent Singapore study.

Levels of the proinflammatory cytokine interleukin (IL)-6 seem to be associated with psychosomatic symptoms in patients with heart failure (HF), reports a recent study.

Patients with moderate or severe mitral regurgitation who have been admitted for heart failure exacerbation or has an elevated right atrial pressure, renal dysfunction, anaemia, or lacks a mitral valve intervention suffer a greater risk of all-cause mortality, reveals a study.

Eating fish can reduce the risk of stroke, but the benefit is dictated by how fish is prepared and how often it is consumed, according to a study. Specifically, frequent consumption of baked or broiled fish is protective while regular consumption of fried fish contributes to a risk increase, which differs by socioeconomic status.

Low levels of blood pressure (BP) appear to elevate the risk of developing open-angle glaucoma (OAG), reveals a recent US study. In addition, there is no evidence supporting a differential effect of medically treated and untreated low BP.

The fibrosis-4 index (FIB-4) is strongly and independently associated with major adverse cardiovascular events (MACE), beyond established cardiovascular risk factors and baseline liver diagnosis, among patients with nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), or at risk of NASH, a study in the real-world setting has shown.

A knowledge gap exists on the effects of direct oral anticoagulants (DOACs), but most nonvalvular atrial fibrillation (NVAF) patients with liver disease still begin treatment with these medications, particularly apixaban and rivaroxaban, a study has found.